NY-DILIGENT
17.5.2023 15:01:30 CEST | Business Wire | Press release
Diligent, the global leader in modern governance providing SaaS solutions across governance, risk, compliance, audit and ESG, today announces the launch of Diligent Showcase, a central hub for customers to enhance their GRC and ESG program with more than 50 partners and integrations. The showcase features technology integrations, complementary solutions, and Diligent authorized service providers.
“Diligent Showcase makes it easy for our customers to quickly identify app integrations, solution providers, consultants and independent software vendors that are verified Diligent partners and best positioned to meet their unique business goals,” said Ricardo Moreno, SVP of Worldwide Partnerships at Diligent. “The Showcase underscores our commitment to delivering value to our customers through partnerships and integrations, and also brings visibility to the unique value our partners bring to help our mutual customers better respond to increasing demands for connected GRC solutions.”
Diligent Showcase is an extension of The Diligent Partner Program, the first program to offer partners a single source to meet all their GRC and ESG needs. Using Diligent Showcase, customers can search Diligent’s expansive partner network by region or solution type to find the right partners, integrations, and content to help them tackle the evolving landscape of GRC and ESG. Customers can connect with partners directly or speak with a Diligent expert to find the applications and partners best suited to their needs. Partners in the Diligent Showcase fall into three categories:
- Technology integrations that enable customers to leverage third party solutions within the Diligent platform, such as Clarity AI, Bitsight, S&P Global, Glass Lewis and more.
- Complementary solutions or services that pair with the Diligent platform to enhance an organization’s GRC or ESG program, including Corporation Service Company, Best in Governance (BIG), Board Excellence, Donnelley Financial Solutions (DFIN), Law Debenture and more.
- Solution providers that are trained and authorized to provide Diligent solutions as part of their offerings, including Vertosoft, Turnkey and more.
“Diligent shares our passion for helping organizations stay ahead of global regulatory and compliance requirements, and other business risks, through innovative software,” said Craig Clay, President, Global Capital Markets at Donnelley Financial Solutions (DFIN). “Diligent Showcase allows us to highlight our unique value offerings and reach new customers, furthering our GRC practice.”
“‘Through Bitsight’s integration with Diligent, public and private companies will be able to access market-leading risk data and insights within their Diligent solution, giving them a more holistic view of their cyber risk profile,” said Steve Harvey, CEO at Bitsight. “As the category creator and global leader in the cybersecurity ratings industry, we’re excited to partner with Diligent to help business leaders, risk leaders and boards more confidently navigate the uncertain cyber landscape.”
Learn more about the Diligent Showcase here or become a Diligent partner here.
About Diligent
Diligent is the global leader in modern governance, providing SaaS solutions across governance, risk, compliance, audit and ESG. Empowering more than 1 million users and 750,000 board members and leaders with a holistic view of their organization’s GRC practices so they can make better decisions, faster. No matter the challenge. Learn more at diligent.com.
Follow Diligent on LinkedIn, Twitter and Facebook.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230517005174/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom